Brattle was engaged by a large pharmaceutical manufacturer to evaluate whether the manufacturer had met its contractual obligations for promoting a product that it had licensed from a smaller drug company. We presented evidence concerning the probability that a drug in development would eventually be approved by the FDA and evaluated the plaintiff’s damages estimates.

Practices